- Clinical Experience
- Rheumatology
- Pulmonology
- Ophthalmology
- Nephrology
- Neurology
- Proposed MOA
- Dosing & Duration
- Safety Data
- Acthar Patient Support
- Resources & Videos
Acthar Patient Support is available. Learn more.
Baughman RP, Sweiss N, Keijsers R, Birring SS, Shipley R, Saketkoo LA, Lower EE—Lung, 2017
Disclosure statement: Funding to support this study was provided by Mallinckrodt Pharmaceuticals.
To evaluate Acthar Gel in patients with advanced pulmonary sarcoidosis who were receiving prednisone and experiencing deterioration of pulmonary disease
TNF=tumor necrosis factor.
*Five patients stopped the loading schedule at Days 7 through 9 due to toxicity.
Primary Endpoint
Additional Assessments
Chronic, advanced sarcoidosis patients in the study had multi-organ involvement, with progressive disease
Following treatment with Acthar Gel, there was a reduction in prednisone dose at 7 weeks that persisted through 24 weeks (n=16).
Daily prednisone dosages at Weeks 0, 7, and 24 (n=16)1
*Prednisone dose administered QOD (every other day).
†At Week 7, prednisone dose administered 3 times per week.
Acthar Gel may be an alternative treatment for advanced sarcoidosis patients.
Start the referral process for your appropriate patients
Acthar® Gel is indicated for:
Contraindications
Acthar is contraindicated:
Warnings and Precautions
Adverse Reactions
Pregnancy
Please see full Prescribing Information for additional Important Safety Information.
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References: